Variant · Snv
FLT3 F691L
CI-VAR-00001130Explore in graph →CIViC 3071
Curated evidence
Evidence by cancer (15 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30651561
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia14 | ||||||||
| FLT3 F691L | Crenolanib | Predictive | D | Supports Resistance | 5 | submitted | EID12387FLT3 F691L was observed in 2 patient samples collected after at least 28 days of treatment with crenolanib. Prior to treatment with crenolanib, both patients were treated with quizartinib. Ba/F3 cells… (full text at CIViC) PMID 30651561 · Zhang et al., 2019 · Open in CIViC | civic |
| FLT3 F691L | FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | Predictive | D | Supports Resistance | 3 | submitted | EID8846A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available